As Sanofi works to gain traction for the launch of its world-first dengue vaccine, a potential competitor may be building its case. This week, the National Institutes of Health announced that a candidate developed by scientists there posted "very encouraging" results, according to the team's lead scientist.
The high-stakes rollout of Sanofi's dengue vaccine, Dengvaxia, is slated this month in the private market, the lead executive for the product said, adding that a tender for 3 million doses is in advanced discussions in the Philippines for a public launch within weeks.
A dengue fever vaccine developed by scientists at the National Institute of Allergy and Infectious Diseases is entering a Phase III in Brazil that aims to enroll nearly 17,000 people in 13 cities.
Sanofi Pasteur spent 20 years and $1.5 billion researching its dengue fever vaccine, Dengvaxia, and now it's looking to maximize the vaccine's impact. To do that, the French pharma's vaccine division is working with regulators and health officials to identify implementation strategies, program head Guillaume Leroy told FierceVaccines.
A waiver of large-scale clinical trials for Sanofi's dengue vaccine, Dengvaxia, was recommended by a special committee that advises the Drug Controller General of India, the Economic Times reports.
Days after Sanofi received its first approval in Mexico for its pioneering dengue fever vaccine, it's said to be in discussions to bring the jab to India following a successful trial on an adult population there.
Seeking a dengue fever vaccine that can offer broad protection in a short time, the U.S. Army has awarded Hawaii Biotech a Phase I contract to support the company's work against the "potentially mission-aborting" disease, according to a press release.
Sanofi is the furthest along in the race for a dengue vaccine, expecting its first license to market its jab by the end of the year. But this doesn't mean others aren't trying to tackle the mosquito-borne disease: SUNY Upstate Medical University announced on Monday a $12 million partnership with the U.S. Army to develop a dengue vaccine.
After Sanofi's sizable investment into its dengue vaccine program, new company CEO Olivier Brandicourt said on the Q3 call that the French pharma expects its first license to market the vaccine by year end.
Sanofi CEO Olivier Brandicourt and his executive team had good words to say about business in China and emerging markets for therapies in the chronic disease category, helping the company's pharma operations jump a whopping 16% in currency-adjusted gains in the Middle Kingdom as it expanded further into second-tier cities.